In the current guidelines on prostate cancer, which were published in December 2016, the international data has now been shown(finally) , that there is no recommendation on primary curative treatment with brachytherapy in prostate cancer (PSA> 10 ng / ml or Gleason> 7 or tumor stage > PT2).
This has now taken account of developments in Germany, which have been so marked since 2004.
The transperineal application of implants with iodine 125, radiation dose 145 Gy, or palladium-103, radiation dose 125 Gy, has spread rapidly since the mid-1990s in the USA, but also in Europe and Germany. The reintroduction of the method is due to the new development of software for the targeted implant according to an implant plan as well as to the improvement of the transrectal ultrasound examination. Until 2004 the published results were also comparable to the “radical prostatectomy”.
20 years after the introduction of brachytherapy in prostate cancer, there is as yet no single randomized controlled study regarding their therapy effects compared to radical prostatectomy, percutaneous radiation therapy and / or against “watchful waiting” or “active surveillance”. Thus, no reliable statements about the advantages or disadvantages or the equivalence of this method can be made against other therapy options.
This fact is in sharp contradiction to the full-bodied statements in the high-gloss images of some radiation therapy institutes.